News

Cardiff Oncology's onvansertib shows a 64% response rate in early colorectal cancer trials. Click here to read an analysis of ...
Cancer patients who receive COVID boosters are far less likely to be hospitalized, but vaccination rates remain alarmingly ...
Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...
The rising median age of people around the world has the same effect, since cancer can take decades to develop and therefore ...
Although data from 1975 to 1997 revealed a gap in cancer survival improvement in adolescents and young adults (AYAs; 15-39 years) compared with children and older adults, more recent studies have ...
Medical specialists often order a multiparametric MRI (mpMRI) following elevated PSA levels to determine if biopsies are ...
Prostate cancer focal therapies include cryotherapy, irreversible electroporation ablation (IRE), & high-intensity focused ultrasound (HIFU).
A large Department of Veterans Affairs cohort study revealed key racial differences in genomic alterations among men with metastatic prostate cancer.
A clinical trial is launching to test the effectiveness of new tests that aim to detect genetic signatures of cancer in the blood.
Men diagnosed with nonmetastatic low- and intermediate-risk prostate cancer up to 6 times more likely to die of other causes.